1. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy
- Author
-
Ilson, David H., Tabernero, Josep, Prokharau, Aliaksandr, Arkenau, Hendrik-Tobias, Ghidini, Michele, Fujitani, Kazumasa, Van Cutsem, Eric, Thuss-Patience, Peter, Beretta, Giordano D., Mansoor, Wasat, Zhavrid, Edvard, Alsina, Maria, George, Ben, Catenacci, Daniel, McGuigan, Sandra, Makris, Lukas, Doi, Toshihiko, Shitara, Kohei, Universitat Autònoma de Barcelona, Ilson, David H., Tabernero, Josep, Prokharau, Aliaksandr, Arkenau, Hendrik-Tobias, Ghidini, Michele, Fujitani, Kazumasa, Van Cutsem, Eric, Thuss-Patience, Peter, Beretta, Giordano D., Mansoor, Wasat, Zhavrid, Edvard, Alsina, Maria, George, Ben, Catenacci, Daniel, McGuigan, Sandra, Makris, Lukas, Doi, Toshihiko, Shitara, Kohei, and Universitat Autònoma de Barcelona
- Abstract
This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy. Is trifluridine/tipiracil treatment safe and effective for the subpopulation of patients with previously treated metastatic gastric or gastroesophageal junction cancer who have undergone gastrectomy? In this subgroup analysis of a randomized clinical trial, trifluridine/tipiracil treatment improved overall survival and progression-free survival compared with placebo among patients with previously treated metastatic gastric or gastroesophageal junction cancer and who had or had not undergone gastrectomy. No new safety concerns were reported, and hematologic toxic effects were more frequent among the subgroup who had undergone gastrectomy but were treated using dosing modifications. Trifluridine/tipiracil is a safe and effective treatment option for patients with pretreated metastatic gastric or gastroesophageal junction cancer regardless of previous gastrectomy. Trifluridine/tipiracil (FTD/TPI) treatment has shown clinical benefit in patients with pretreated metastatic gastric cancer or gastroesophageal junction cancer (mGC/GEJC). Patients who have undergone gastrectomy constitute a significant proportion of patients with mGC/GEJC. To assess the efficacy and safety of FTD/TPI among patients with previously treated mGC/GEJC who had or had not undergone gastrectomy. This preplanned subgroup analysis of TAGS (TAS-102 Gastric Study), a phase 3, randomized, placebo-controlled, clinical trial included patients with mGC/GEJC who had received at least 2 previous chemotherapy regimens, and was conducted at 110 academic hospitals in 17 countries in Europe, Asia, and North America, with enrollment between February 24, 2016, and January 5, 2018; the data cutoff was March 31, 2018. Patients were ra
- Published
- 2019